Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild Dementia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Passport to Brain Wellness in Sedentary Adults

NCT00979446
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Guided, Self-directed
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
60 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Riluzole in Mild Alzheimer's Disease

NCT01703117
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

NCT07553338
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
Interventions
Leronlimab (700mg)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Not applicable Interventional

δ in Dementia Clinical Trials

NCT05592678
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Interventions
Donepezil
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

NCT01825330
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TMS and cognitive stimulation, sham
Device
Lead sponsor
Neuronix Ltd
Industry
Eligibility
60 Years to 90 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sun City, Arizona • Costa Mesa, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

NCT01264614
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Strengthening exercise
Behavioral
Lead sponsor
Union College, New York
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)

NCT02414282
View directory record Official record
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Not listed No phase listed Observational

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT06400368
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
NeuroVision Imaging
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jul 23, 2026, 2:43 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

NCT07417891
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis, Mild Cognitive Impairment, MCI, Mild Cognitive Impairment (MCI), Dementia
Interventions
Well-formulated ketogenic diet
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
55 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

NCT02783573
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 4 Interventional Results available

Modafinil Treatment for Sleep/Wake Disturbances in Older Adults

NCT00626210
View directory record Official record
Conditions
Insomnia, Sleep Initiation and Maintenance Disorders, Alzheimer Disease
Interventions
modafinil
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

NCT02573740
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
ABT-957, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

NCT03933696
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT03347084
View directory record Official record
Conditions
Brain Imaging, Mild Cognitive Impairment, Alzheimer Disease, Deep Brain Stimulation
Interventions
Excitation, Inhibition
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00103649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-957, Placebo for ABT-957
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Glendale, California • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

NCT00297414
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
No intervention
Other
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
Not listed
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
50
States / cities
Tucson, Arizona • Laguna Woods, California • Northridge, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03444870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

NCT05877196
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Interventions
Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 2:43 AM EDT